Ipsen announced that it has avoided an interruption in the U.S. supply of Increlex (mecasermin [rDNA origin] soln for inj) due to delays in manufacturing site approval. The active principle (IGF-1) for the treatment of Severe Primary IGF-1 Deficiency (Primary IGFD) is manufactured by Lonza Biologics Inc. at its Hopkinton, MA facility. Since Increlex is deemed a drug of medical necessity, Ipsen and the FDA have worked closely together to maintain supply.
Increlex 10mg/mL is indicated for the treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) or in those with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH.
For more information call or visit www.increlex.com.